13 results about "Phosphatidylserine" patented technology

A reagent for measuring activated partial thromboplastin time, the reagent comprising phosphatidylcholine (PC), phosphatidylserine (PS), and phosphatidylethanolamine (PE), wherein the ratio (PS / PC) of the concentration of the PS to the concentration of the PC is 0.26-2.00, and the concentration of the PS is 14-60 µg / mL.

The invention discloses a dietary therapy formula for preventing senile dementia, improving memory, repairing a conducted nervous system and dredging damaged brain nerves, and belongs to the technical field of dietary therapy health care. According to the formula, functional nutritional ingredients, bioactive peptides, medicinal and edible extracts and compound probiotics are taken as cores, and the formula is prepared through scientific proportioning; the health-care food specifically comprises xylitol, isomaltooligosacharide, N-acetylneuraminic acid, phosphatidylserine, bovine brain peptide, walnut peptide, shark peptide, acer truncatum seed oil microcapsule powder, DHA algal oil microcapsule powder, spina date seeds, tea theanine, gamma-aminobutyric acid, Belgian imported inulin, magnesium stearate, and 16 optional specific probiotics and metabiotics. The formula follows a multi-dimensional synergistic principle of nutrition supply-nerve repair-function regulation-absorption synergy, the core component can penetrate through a blood brain barrier, supplement nerve repair raw materials, repair damaged nerve cells and myelin sheaths and regulate neurotransmitter balance, and the probiotics indirectly assist nerve maintenance through intestinal tract-nerve axis, so that the composition has the effects of promoting blood circulation and promoting blood circulation. The synergistic effects of preventing senile dementia, improving memory and repairing and dredging a nervous system are achieved; the raw materials are food-grade safe components, have no side effects, can be prepared into powder, tablet candies and other forms, are convenient to eat and suitable for long-term conditioning, and solve the problems of single component, insufficient repair pertinence and low absorption efficiency of existing nerve care products.

The invention discloses a phospholipid hydrophilic chromatographic separation and evaporative light scattering detection method suitable for liquid milk, milk powder and milk source raw materials. The method comprises the following steps: preparing a sample solution from a sample to be detected; extracting the sample solution by using a solution of chloroform and methanol to obtain subnatant as extract liquor; adding a saturated salt solution into the extract liquor for chromatographic purification, and taking separated lower clear liquid as purified liquid; preparing the purified liquid into a sample introduction liquid; and determining the phospholipid content in the sample injection solution by using a liquid chromatography-evaporative light scattering detector. In the detection method, a sample solution is extracted by using a solution of chloroform and methanol, and a saturated salt solution is added into an extraction solution for chromatographic purification, so that chromatographic peaks are not interfered, and various phospholipids in food can be accurately measured at the same time; the method can be used for simultaneously determining phosphatidylcholine, sphingomyelin, phosphatidyl ethanolamine, phosphatidylserine and phosphatidylinositol in food, and has the advantages of simplicity, rapidness, accuracy, low detection limit and high sensitivity.

The application relates to a preparation method of immobilized phospholipase D and a preparation method of phosphatidylserine thereof, and belongs to the technical field of biotechnology.The preparation method of the immobilized phospholipase D comprises the following steps: (1) mixing mesoporous molecular sieve SBA-15 and a sodium acetate buffer solution to obtain a mixed solution; (2) mixing the mixed solution with an enzyme solution, oscillating, centrifuging, taking the precipitate, cleaning and freeze-drying to obtain the immobilized phospholipase D.The application improves the catalytic performance and stability of PLD by fixing PLD through the immobilization technology, realizes the reusability of PLD, and provides technical support for the industrialized production of the immobilized enzyme of PS.The preparation of phosphatidylserine by the immobilized PLD is optimized, and the optimal process condition of the preparation of PS by the immobilized PLD is obtained.The application further discloses a potential molecular mechanism of PS in treating AD, and provides a theoretical basis for the further clinical application of PS.

The invention discloses a novel oil-soluble micelle preparation. The component A comprises lecithin, soya bean lecithin, egg yolk lecithin, 1-palmitoyl-2-oleoyl lecithin, phosphatidylserine, phosphatidylinositol, phosphatidyl glycerol, cardiolipin, cephalin and dipalmitoyl phosphatidylcholine, and the component B comprises lecithin, soya bean lecithin, egg yolk lecithin, 1-palmitoyl-2-oleoyl lecithin, phosphatidylserine, phosphatidylinositol, phosphatidyl glycerol, phosphatidylcholine, cephalin and dipalmitoyl phosphatidylcholine; one or more of dipalmitoyl phosphatidyl ethanolamine and dipalmitoyl phosphatidyl ethanolamine; the component B comprises a component B1 and a component B2, and the component B1 comprises one or more of phytosterol, cholesterol, ergosterol, protopanoxadiol, protopanaxatriol, ganoderic acid, phytol, isophytol, retinol, andrographolide, paclitaxel, artemisinin and bisabolol; and the component B2 is prepared from one or more of 1, 2-hexanediol, ethylhexylglycerin, cyclohexyl glycerin, absolute ethyl alcohol and isosorbide dimethyl ether. The key point of the invention is to provide a low-cost formula and a low-cost preparation method for preparing the oil-soluble micelle preparation.

This invention provides a composite composition containing nervonic acid and its use in brain nerve repair, belonging to the field of biotechnology. The invention uses nervonic acid and phosphatidylserine, combined with plant extracts fermented by a microbial concoction of *Lactobacillus acidophilus*: *Lactobacillus rhamnosus*: *Bacillus belyssae* = (2-3):1:1, to form a composite composition. This scientific formulation achieves synergistic effects from multiple components, improving neurological deficits, reducing cerebral infarction volume, decreasing the release of neurotrophic markers, and upregulating neurotrophic factor expression through multi-target synergistic effects. Furthermore, this synergistic effect depends on specific component ratios, providing crucial experimental support for the development of subsequent brain-protective functional compositions. This composition can be widely applied to the preparation of brain nerve repair drugs, functional foods, and dietary supplements, possessing promising industrialization prospects and clinical value.

The invention relates to an anti-prothrombin / phosphatidylserine antibody, a pharmaceutical composition and an application of the anti-prothrombin / phosphatidylserine antibody. The anti-prothrombin / phosphatidylserine antibody provided by the invention is connected with a prothrombin / phosphatidylserine compound with high affinity, so that the antibody is combined with phosphatidylserine in a targeted manner to achieve the treatment of tumor resistance, infection resistance, thrombosis resistance, atherosclerosis, ischemia-reperfusion injury, inflammatory bowel disease, Alzheimer's disease and Parkinson's disease.

A caffeine-free, ready-to-drink liquid composition is provided for pre-caffeine cognitive priming. A unit dose of about 2.0 to 3.0 ounces at pH about 3.0 to 3.5 comprises N-acetyl L-tyrosine, citicoline, phosphatidylserine, one or more adaptogenic botanicals, L-citrulline, piperine, vitamins B6 and B12, a magnesium source, and an acidulant system including malic acid with limited citric acid. A sensory agent, such as ginger CO2 extract, yields perceivable warming or tingling within minutes, with palate clearance in about sixty seconds. Methods include administering the composition about 2 to 45 minutes before consuming a caffeinated beverage to provide rapid, predictable onset while maintaining beverage flavor compatibility. Packaged systems may use nitrogen-flushed PET or glass, cold-fill, and high-pressure processing or low-temperature pasteurization, with optional low-level carbonation and microencapsulation to manage bitterness, dissolution, and stability.

Compositions containing lipid nanoparticles and nucleic acid therapeutic agents are disclosed. For example, calcium phosphate nanoparticles having a lipid coating are provided, wherein the calcium phosphate nanoparticles include a cyclic dinucleotide and the lipid coating includes phosphatidylserine. The compositions can be formulated for administration to the lungs of a subject via inhalation, or for administration via injection. Methods for the treatment of lung cancer and other cancers are also described. Targeted delivery of therapeutic agents such as cyclic dinucleotides to antigen presenting immune cells via the disclosed methods can elicit beneficial antitumor immunity.

The utility model discloses an extraction separation device for preparing phosphatidylserine relates to extraction separation equipment technical field. Including extraction box and separation tank, the extraction box is with separation tank from top to bottom setting and is provided with first solenoid valve between both, the extraction box top is provided with the feeding opening, is provided with stirring scraping wall mechanism in the extraction box, is provided with detachable filter assembly in the separation tank. The utility model can scrape wall operation to extraction tank while stirring in the extraction tank, and the stirring efficiency is higher and avoids the attachment material of extraction tank inner wall, and the detachable filter assembly is convenient to replace filter separation piece, and guarantees separation function stability.

Provided herein is a composition of substances preferably obtained from natural sources, which is effective in preventing and / or treating iron deficiency conditions or diseases. The composition includes iron pyrophosphate, phosphatidylserine, phosphatidylcholine and starch, preferably acetylated pregelatinised starch. The formulation gives the composition gastro-resistance properties and high bioavailability of the active ingredient iron pyrophosphate. The composition is prepared in the form of a solid, semi-solid or liquid pharmaceutical dosage, preferably for oral administration.

The application relates to the technical field of detection analysis, and particularly discloses a DNA-nano silver cluster, a preparation method and application thereof. The application rapidly identifies the everted level of phosphatidylserine in blood cells through a composite nano silver cluster fluorescence sensing array technology, thereby realizing real-time prediction of disseminated intravascular coagulation of sepsis, filling the blank of the sepsis DIC prediction method, and avoiding the lag of the existing sepsis DIC diagnosis, so that a new time window is provided for sepsis DIC treatment.

The invention provides a characteristic phospholipid molecular biomarker in plasma, a screening method thereof and application of the characteristic phospholipid molecular biomarker in preparation of a kit for diagnosing pneumoconiosis. The characteristic phospholipid molecules at least comprise the following nine phospholipid molecules: lysophosphatidylcholine (12: 0), phosphatidylcholine (16: 0 / 16: 0), phosphatidylcholine (18: 0 / 18: 1), phosphoinositide (16: 0 / 18: 1), lysophosphatidic acid (16: 0), phosphatidyl glycerol (16: 0 / 16: 0), phosphatidylserine (18: 1 / 18: 1), phosphatidylcholine (18: 0 / 20: 2) and lysophosphatidyl ethanolamine (18: 2). The TC value is calculated by calculating the quantitative values of the nine characteristic phospholipid molecules and a classification model constructed based on a support vector machine algorithm, the risk of pneumoconiosis is predicted according to the TC value, pneumoconiosis patients and non-pneumoconiosis patient groups can be accurately distinguished, and the method is used for pneumoconiosis diagnosis and early screening.